Parkman Healthcare Partners’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Parkman Healthcare Partners’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,753,630	Closed	-$7.37M	–	108
2023 Q1	$7.37M	Buy	1,753,630 +344,988	+24%	+$1.79M	1.6%	25
2022 Q4	$8.47M	Buy	1,408,642 +198,497	+16%	+$1.08M	2.25%	12
2022 Q3	$7.04M	Buy	1,210,145 +159,098	+15%	+$991K	2%	17
2022 Q2	$6.28M	Buy	1,051,047 +826,047	+367%	+$4.23M	2.31%	16
2022 Q1	$1.05M	Buy	+225,000	New	+$671K	0.31%	66

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Parkman Healthcare Partners's CTIC Position: Q2 2023 in Review

Parkman Healthcare Partners sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 1,753,630 shares — an estimated $7.37M sold.

Parkman Healthcare Partners first reported a position in CTIC in Q1 2022 and held it in 5 quarters. The position peaked at $8.47M in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Parkman Healthcare Partners reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Parkman Healthcare Partners sold 1,753,630 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $7.37M.
Parkman Healthcare Partners first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2022 and held it in 5 quarters.
Parkman Healthcare Partners's CTI BioPharma Corp. (DE) Common Stock position peaked at $8.47M in Q4 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Parkman Healthcare Partners's 13F filing for Q2 2023, filed 11 Aug 2023.